Diabetes Drug May Slow Parkinson’s Disease
In an accompanying commentary, Werner Poewe, MD, and Klaus Seppi, MD, from Medical University Innsbruck, Austria, note the findings of a potential new mechanism in the treatment of Parkinson’s disease are “exciting,” but there are several caveats.
“First, the groups were unbalanced at baseline: patients in the exenatide arm were older and had higher MDS-UPDRS part 3 scores and lower total levodopa-equivalent doses than did those in the placebo group,” they write.
Also, patients in the exenatide group had somewhat greater increases in their concomitant dopaminergic therapy over the course of the trial relative to peers in the placebo group. While the investigators tried to adjust for this discrepancy, “a confounding effect for differences in concomitant dopaminergic therapy during the trial cannot be excluded,” they add.